Metformin Mechanism

Metformin is a biguanide widely used in the treatment of type 2 diabetes mellitus. It has been shown that this compound ameliorates hyperglycemia without promoting insulin secretion, causing weight gain, or generating hypoglycemia. Convincing data place energy metabolism at the center of metformin’s mechanism of action in treating diabetes, which may also be of importance in cardiovascular diseases and cancer.

METFORMIN MECHANISM OF ACTION MADE SIMPLE *ANIMATED*

Diabetes mellitus

Several different mechanisms are included in the reduction of serum glucose level by metformin without increasing insulin secretion, predominantly via non-pancreatic pathways. Metformin is often referred to as an insulin sensitizer, as it increases the effects of insulin. Metformin also suppresses endogenous glucose production in the liver by reducing the rate of gluconeogenesis with little impact on cellular ATP levels.

AMP-activated protein kinase (AMPK) represents a target capable of mediating the beneficial metabolic effects of metformin. AMPK is a multisubunit enzyme that is recognized as a major regulator of lipid biosynthetic mechanisms due to its role in the phosphorylation and subsequent inactivation of pivotal enzymes, such as acetyl-CoA carboxylase. A plethora of pharmacological and genetic studies demonstrate that AMPK is required for maintaining glucose homeostasis.

Recent research strongly suggests that AMPK has a wider role in metabolic regulation, which includes muscle glucose uptake, fatty acid oxidation, expression of specific gluconeogenic genes (such as G6Pase), and glucose-stimulated genes linked to hepatic lipogenesis including fatty acid synthase, Spot-14, and pyruvate kinase. Thus, metformin is an ideal therapeutic target for type 2 diabetes mellitus.

Chronic activation of AMPK may also induce the expression of muscle hexokinase and glucose transporters, mimicking the effects of extensive exercise training. Metformin has also demonstrated protective properties against diabetic complications, especially by reducing the diabetes-related death rate.

Polycystic ovarian syndrome

Women with the polycystic ovarian syndrome (PCOS) present with diverse phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The eventual presence of hyperinsulinemia is an important parameter to decide whether or not to initiate metformin therapy for women with PCOS in order to prevent or delay the onset of type 2 diabetes mellitus.

Lifestyle interventions such as dietary improvement and aerobic exercise remain the cornerstone of effective long-term health improvement for overweight women with PCOS. Still, studies have shown that metformin improves ovulation, hyperandrogenism, and abnormal lipid profile in these patients. Based on these data, the use of metformin is often recommended for the treatment of metabolic syndrome, which may act as a suitable alternative to oral contraceptive pills.

Metformin has the potential to be considered as a therapy of choice prior to laparoscopic ovarian drilling or gonadotrophin injection therapy. On the other hand, more research is needed in order to define this agent's role in improving long-term health outcomes for women with PCOS, including the prevention of diabetes and cardiovascular disease.

Cancer prevention

Various preclinical studies have shown reliable anti-tumor effects for metformin in different animal models. Metformin has also been associated with strong beneficial and antiproliferative effects on breast, ovarian, prostate, lung, pancreatic, colon, and breast cancers, which was confirmed in clinical trials for the latter three malignancies.

It has been observed that in early-stage breast cancer of non-diabetic women, metformin reduced fasting insulin by 22% and improved several metabolic parameters. Large case-control studies showed that the risk of pancreatic cancer in a group receiving metformin treatment was 62% lower than in the placebo group.

Anticancer metabolic effects of metformin also occur through direct modulation of metabolic genes and microRNAs (miRNAs). Currently, there are numerous trials underway with metformin as the potential drug in prostate cancer patients receiving androgen deprivation therapy, as well as in patients with small benign thyroid nodules and insulin resistance.

Metformin was also employed as adjuvant therapy in cancer patients, and most of the cancer clinical trials of metformin use the doses which are typical for treating diabetes. Diabetes prevention and regulation of circadian clock represent future therapeutic perspectives for metformin.

References

Further Reading

Last Updated: Mar 31, 2021

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2021, March 31). Metformin Mechanism. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/health/Metformin-Mechanism.aspx.

  • MLA

    Meštrović, Tomislav. "Metformin Mechanism". News-Medical. 31 October 2024. <https://www.news-medical.net/health/Metformin-Mechanism.aspx>.

  • Chicago

    Meštrović, Tomislav. "Metformin Mechanism". News-Medical. https://www.news-medical.net/health/Metformin-Mechanism.aspx. (accessed October 31, 2024).

  • Harvard

    Meštrović, Tomislav. 2021. Metformin Mechanism. News-Medical, viewed 31 October 2024, https://www.news-medical.net/health/Metformin-Mechanism.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidate reverses obesity in mice by transforming liver metabolism